On December 18, 2024, the Food and Drug Administration sanctioned remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-r...
Cancer remains one of the most challenging diseases to treat, requiring innovative and effective therapies. One of the most promising advancements in cancer treatment is Chimeric Antigen Receptor (CA...
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
IntroductionHematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic system. Conventional trea...
CAR T Cell therapyChimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary therapeutic strategy in hematologic malignancy treatment, recording high remission rates in therapy-refractory cas...
IntroductionCancer is still one of the most difficult diseases to cure, and conventional treatments such as chemotherapy, radiation, and surgery have yielded limited success and severe side effects....
CAR immune Cell therapyChimeric Antigen Receptor (CAR) immune cell therapy has transformed the treatment of cancer, especially for hematological cancers. Its effectiveness notwithstanding, it still ...
CAR T Cell therapyChimeric Antigen Receptor (CAR) T-cell therapy has changed the face of treating B-cell malignancies, and it has provided hope to those with relapsed or refractory disease. Through ...
CAR T Cell therapyChimeric Antigen Receptor (CAR) T cell therapy has transformed cancer treatment by genetically modifying a patient's own T cells to target and destroy cancer cells. Although this a...
CAR T Cell therapyChimeric Antigen Receptor (CAR) T-cell therapy has changed the course of treatment for numerous hematologic malignancies like leukemia, lymphoma, and multiple myeloma. China is at ...